InVivo Therapeutics Corp... (NVIV)
NASDAQ: NVIV
· Real-Time Price · USD
0.32
-0.17 (-34.43%)
At close: Feb 12, 2024, 9:00 PM
Company Description
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI).
It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI.
The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
InVivo Therapeutics Corporation
| Country | United States |
| IPO Date | Nov 15, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Dr. Richard M. Toselli M.D. |
Contact Details
Address: One Kendall Square Cambridge, Massachusetts United States | |
| Website | https://www.invivotherapeutics.com |
Stock Details
| Ticker Symbol | NVIV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001292519 |
| CUSIP Number | 46186M605 |
| ISIN Number | US46186M6057 |
| Employer ID | 00-0000000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Richard M. Toselli M.D. | President, Chief Executive Officer, Chief Medical Officer & Director |
| Heather M. Hamel J.D. | Chief Legal Officer & General Counsel |
| Richard C. Christopher | Chief Financial Officer & Treasurer |
| Dr. Joseph Philip Vacanti M.D. | Co-Founder |
| Dr. Robert S. Langer Jr., Ph.D. | Co-Founder & Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2024 | 25-NSE | Filing |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 07, 2024 | 4/A | [Amend] Filing |
| Feb 07, 2024 | 4 | Filing |
| Feb 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 06, 2024 | 8-K | Current Report |
| Feb 01, 2024 | 8-K | Current Report |
| Jan 03, 2024 | 8-K | Current Report |
| Dec 05, 2023 | ARS | Filing |